N- and C-terminal modifications of negamycin

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 14, 2003, Pages 2413-2418

  Raju, B ^a   Mortell, Kathleen ^a   Anandan, Sampathkumar ^a   O'Dowd, Hardwin ^a   Gao, Hongwu ^a   Gomez, Marcela ^a   Hackbarth, Corinne ^a   Wu, Charlotte ^a   Wang, Wen ^a   Yuan, Zhengyu ^a   White, Richard ^a   Trias, Joaquim ^a   Patel, Dinesh V ^a  

^a Versicor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA AMINO ACID; NEGAMYCIN;

AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; SEPTICEMIA; STRUCTURE ACTIVITY RELATION;

ESCHERICHIA COLI; MURINAE; NEGIBACTERIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 10744222313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00393-7     Document Type: Article

References (37)

1. Travis J. Science. 264:1994;360.
2. (b) Davis J. Science. 264:1994;375.
3. Moellering R. Clinc. Infect. Dis. 27:1998;135.
4. Buysse J. Current Med. Chem. 8:2001;1713.
5. Singh M.P., Greenstein M. Curr. Opin. Drug Discov. Dev. 6:2000;101.
6. (b) Brands M., Endermann R., Gahlmann R., Kruger J., Raddatz S., Stoltefuβ J., Belov V.N., Nizamov S., Sokolov V.V., de Meijere A. J. Med. Chem. 45:2002;4246.
7. (c) Brooks G., Burgess W., Clothurst D., Hinks J., Hunt E., Pearson M.J., Shea B., Takle A., Wilson J.M., Woodnutt G. Bioorg. Med. Chem. 9:2001;1221.
8. Hamada M., Takeuchi T., Kondo S., Ikeda Y., Naganawa H., Maeda K., Okami Y., Umezawa H. J. Antibiot. 23:1970;170.
9. (a) Mizuno S., Nitta K., Umezawa H. J. Antibiot. 23:1970;581.
10. (b) Mizuno S., Nitta K., Umezawa H. J. Antibiot. 23:1970;589.
11. (c) Uehara Y., Kondo S., Umezawa H., Suzukake K., Hori M. J. Antibiot. 25:1972;685.
12. (d) Uehara Y., Hori U., Umezawa H. Biochim. Biophys. Acta. 374:1974;82.
13. (e) Uehara Y., Hori U., Umezawa H. Biochem. Biophys. Acta. 447:1976;406.
14. (f) Uehara Y., Hori U., Umezawa H. Biochem. Biophys. Acta. 442:1976;251.
15. (a) Kondo S., Yamamoto H., Maeda K., Umezawa H. J. Antibiot. 24:1971;732.
16. (b) Kondo S., Iinuma K., Yoshida K., Yokose K., Ikeda Y., Shimazaki M., Umezawa H. J. Antibiot. 29:1976;208
17. (c) Uehara Y., Hori M., Kondo S., Hamada M., Umezawa H. J. Antibiot. 29:1976;937.
18. (d) Kondo S., Yoshida K., Ikeda T., Iinuma K., Honma Y., Hamada M., Umezawa H. J. Antibiot. 30:1977;1137.
19. (e) Curran W.V., Boothe J.H. J. Antibiot. 31:1978;914.
20. (f) Streicher W., Reinshagen H. Chem. Ber. 108:1975;813.
21. (g) Streicher W., Reinshagen H., Turnowsky F. J. Antibiot. 31:1978;725.
22. 3R-Aminohexene-5-noic acid was purchased from PepTech Corporation, 1770 Massachusetts Av., #663, Cambridge, MA 02140, USA.
23. (a) Wong Y., Izawa T., Kobayashi S., Ohno M. J. Am. Chem. Soc. 104:1982;6465.
24. (b) Cardillo G., Orena M. Tetrahedron. 46:1990;3321.
25. Masters J.J., Hegedus L.S. J. Org. Chem. 58:1993;4547.
26. Fukuyama T., Cheung M., Jow C.-K., Hidai Y., Kan T. Tetrahedron Lett. 38:1997;5831.
27. Muller A., Vogt C., Sewald N. Synthesis. 1998;837. and references cited therein.
28. Rodriguez M., Llinaries M., Doulut S., Heitz A., Martinez J. Tetrahedron Lett. 32:1991;923.
29. Kanai K., Wakabayashi H., Honda T. Org. Lett. 2:2000;2549.
30. Soth M.J., Nowick J.S. J. Org. Chem. 64:1999;276.
31. Ornstein P.L., Schoepp D.D., Arnold M.B., Leander J.D., Lodge D. J. Med. Chem. 34:1991;90.
32. I b i d.
33. Broan C.J., Jasnkowski K.J., Kataky R., Parker D., Randall A.M., Harrison A. J. Chem. Soc., Chem. Commun. 1990;1739.
34. Final compounds were cleaved from resign into 96-well plate and screened against S. aureus ATCC25293, E. coli ATCC25922 and E. coli MG1655. Hits identified from this screen were re-synthesized and their MIC's were determined against an expanded panel of organisms. E. coli MG1655 tolC is an efflux pump mutant.
35. 5 cfu/mL.
36. 50 for negamycin 5.1 mg/kg.
37. Inhibition of protein synthesis was measured with a cell-free transcription/translation coupled assay (E. coli S30 Extract System, Promega, Madison, WI, USA) using pGEMbgal as a DNA template. Compounds were pre-incubated with the reaction mixture for 10 min prior to the addition of template. After 1 h of incubation, ONPG was added and β-galactosidase activity was monitored at 420 nm.